Mereo BioPharma Group plc
MREONasdaq
$0.31
↓ -3.9%Jul 17 close · end-of-day
Price
1Y↓ -82.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$248.6M
Enterprise Value
$212.4M
P/E
—
P/S
—
P/B
7.3
EV/EBITDA
—
PEG
—
FCF Yield
-10.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$48.0M
Free Cash Flow (TTM)
-$27.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
141.1%
ROIC
—
Debt / Equity
—
Net Cash
$36.2M
Return 1Y
-82.6%
Company profile
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.
- CEO
- Denise V. Scots-Knight
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Website
- mereobiopharma.com
Earnings
MREO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.01↓ -50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $10.0M | $0.00 | $500,000.00 |
| Gross profit | — | — | — | — |
| Operating income | -$54.4M | -$28.4M | -$47.4M | -$40.1M |
| Net income | -$42.2M | $29.5M | $43.3M | $41.9M |
| Diluted EPS | -$0.07 | -$0.04 | -$0.06 | -$0.05 |
| Operating cash flow | -$48.8M | -$21.1M | -$32.8M | -$31.0M |
| Free cash flow | -$48.8M | -$21.1M | -$32.8M | -$31.0M |
| Gross margin | — | — | — | — |
| Operating margin | — | -284.2% | — | -8021.4% |
| Net margin | — | 294.7% | — | 8375.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | $500,000.00 | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.8M | -$9.4M | -$15.3M | -$11.2M | -$10.5M | -$10.0M | -$8.4M | -$8.8M |
| Net income | -$12.3M | -$15.0M | $79.5M | -$12.9M | -$14.6M | -$7.0M | $76.4M | -$6.7M |
| Diluted EPS | -$0.02 | -$0.02 | -$0.01 | -$0.02 | -$0.02 | -$0.01 | $0.00 | -$0.01 |
| Operating cash flow | -$7.9M | -$7.5M | -$9.4M | -$8.3M | -$7.7M | -$7.3M | -$7.7M | -$4.3M |
| Free cash flow | -$7.9M | -$7.5M | -$9.4M | -$8.3M | -$7.7M | -$7.3M | -$7.7M | -$4.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -2099.8% | — | — | — |
| Net margin | — | — | — | — | -2923.2% | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.